Allocation of transaction price to licenses.

No definition available.

Name:	bbio_AllocationOfTransactionPriceToLicenses
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Allocation of transaction price to transfer of existing inventory.

+ References

No definition available.

+ Details

Name:	bbio_AllocationOfTransactionPriceToTransferOfExistingInventory
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Initial transaction price for license and collaboration agreement.

+ References

No definition available.

+ Details

Name:	bbio_InitialTransactionPriceForLicenseAndCollaborationAgreement
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Launch milestone payment.

+ References

No definition available.

+ Details

Name:	bbio_LaunchMilestonePayment
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement percentage share of profits and losses.

+ References

No definition available.

+ Details

Name:	bbio_LicenseAgreementPercentageShareOfProfitsAndLosses
Namespace Prefix:	bbio_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses.

+ References

No definition available.

+ Details

Name:	bbio_LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Nonrefundable upfront license fees.

+ References

No definition available.

+ Details

Name:	bbio_NonrefundableUpfrontLicenseFees
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage share of global development costs.

+ References

No definition available.

+ Details

Name:	bbio_PercentageShareOfGlobalDevelopmentCosts
Namespace Prefix:	bbio_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential milestone payments.

+ References

No definition available.

+ Details

Name:	bbio_PotentialMilestonePayments
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Receivable current from licensing and collaboration agreements.

+ References

No definition available.

+ Details

Name:	bbio_ReceivableCurrentFromLicensingAndCollaborationAgreements
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Sale of existing inventory.

+ References

No definition available.

+ Details

Name:	bbio_SaleOfExistingInventory
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront, regulatory and launch milestone payments yet to be received.

+ References

No definition available.

+ Details

Name:	bbio_UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bbio_LicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bbio_HelsinnTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=bbio_QEDTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreement with Helsinn - Additional Information (Details) - USD ($)		3 Months Ended		9 Months Ended
	Mar. 29, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue		$ 2,344,000	$ 8,127,000	$ 56,830,000	$ 8,127,000
Receivable from licensing and collaboration agreements		7,710,000		7,710,000
Research and development		104,305,000	92,050,000	328,824,000	246,873,000
ASC 808
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable from licensing and collaboration agreements		7,700,000		7,700,000
Research and development		9,600,000		28,200,000
License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses		2,600,000		6,800,000
License Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue		1,585,000	$ 8,127,000	55,084,000	$ 8,127,000
License and Collaboration Agreement \| Helsinn Therapeutics
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage share of global development costs	60.00%
License and Collaboration Agreement \| Helsinn Therapeutics \| License Revenue \| ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue		1,600,000		46,000,000.0
Receivable from licensing and collaboration agreements		$ 0		0
License and Collaboration Agreement \| QED Therapeutics, Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront, regulatory and launch milestone payments yet to be received	$ 100,000,000.0
License agreement percentage share of profits and losses	50.00%
Percentage share of global development costs	40.00%
License and Collaboration Agreement \| QED Therapeutics, Inc \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments	$ 2,450,000,000
License and Collaboration Agreement \| QED Therapeutics, Inc \| Helsinn Therapeutics
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial transaction price for the license and collaboration agreement				46,000,000.0
Nonrefundable upfront license fee				20,000,000.0
Sale of certain existing inventory				1,000,000.0
Launch milestone payment				25,000,000.0
Allocation of transaction price to licenses				44,400,000
Allocation of transaction price to transfer of certain existing inventory				$ 1,600,000